Azathioprine as a substitute for 6-mercaptopurine in childhood acute lymphoblastic leukemia: a single-center retrospective study.

Authors

Jianhua Feng, Wenya Qian, Shuqin Shan, Guanling Wang, Jing Wang, Baoqin Shi, Binfei Hu

Published in

Leukemia & lymphoma. Pages 1-9. Jul 06, 2025. Epub Jul 06, 2025.

Abstract

Azathioprine (AZA) is a prodrug that is converted into 6-mercaptopurine (6-MP). Due to the unavailability of 6-MP at our institution, we conducted a post hoc analysis to evaluate the feasibility of using AZA as an alternative therapeutic option across four clinical trials in childhood acute lymphoblastic leukemia (ALL). In total, 93 consecutively treated children with ALL were included. The 7-year overall survival and event-free survival rates were 93% and 87%, respectively. During maintenance therapy, 25 of 78 patients (32.1%) developed grade 1 hepatotoxicity. Among the 42 patients with available hematopoietic toxicity data for the entire maintenance period, the mean percentage of weeks with grade 3-4 leukopenia was 24%, while the mean percentage of weeks with grade 2-4 neutropenia was 44%. Taken together, AZA may serve as an effective alternative to 6-MP for the treatment of childhood ALL. However, enhanced monitoring of treatment-related toxicities is recommended during AZA-based therapy.

PMID:
40618384
Bibliographic data and abstract were imported from PubMed on 07 Jul 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.